Cellectis S.A.
CMVLFOTCHealthcare
$3.47
+$0.39(+12.66%)
Market Cap$250969485
P/E Ratio—
52W High$5.04
52W Low$1.25
Cellectis S.A. (CMVLF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CMVLF · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 11, 2026EPS Actual
-$0.18
Est. -$0.26 · +30.7%
Revenue
$0.01B
Est. $0.01B · -32.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 11, 2026
After Market Close
▲ Beat EPS▼ Miss Revenue✓ 1-Quarter EPS Beat Streak
CMVLF reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$93.32
Rev. $1001.5B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$93.32
Rev. Est.$1001.5B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.26 | — | — | — | $0.01B | — |
| ▲ Q2 FY2026 | May 11, 2026 | -$0.26 | -$0.18 | +30.7% | $0.01B | $0.01B | -32.2% |
| ▼ Q1 FY2026 | Mar 19, 2026 | -$0.21 | -$0.26 | -26.6% | $0.01B | $0.01B | -9.7% |
| ▲ Q4 FY2025 | Nov 7, 2025 | -$0.23 | $0.01 | +102.5% | $0.04B | $0.01B | +242.4% |
| ▼ Q3 FY2025 | Aug 4, 2025 | -$0.22 | -$0.24 | -5.7% | $0.02B | $0.01B | +103.4% |
| ▼ Q2 FY2025 | May 12, 2025 | -$0.15 | -$0.18 | -18.1% | $0.01B | $0.01B | -16.2% |
| ▲ Q1 FY2025 | Mar 13, 2025 | -$0.18 | $0.06 | +132.9% | $0.01B | $0.01B | +38.7% |
| ▲ Q4 FY2024 | Nov 4, 2024 | -$0.24 | -$0.23 | +3.7% | $0.02B | $0.02B | -19.6% |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.26
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 11, 2026Beat
EPS Actual
-$0.18
EPS Est.
-$0.26
EPS Surpr.
+30.7%
Revenue
$0.01B
Q1 FY2026
Mar 19, 2026Miss
EPS Actual
-$0.26
EPS Est.
-$0.21
EPS Surpr.
-26.6%
Revenue
$0.01B
Q4 FY2025
Nov 7, 2025Beat
EPS Actual
$0.01
EPS Est.
-$0.23
EPS Surpr.
+102.5%
Revenue
$0.04B
Q3 FY2025
Aug 4, 2025Miss
EPS Actual
-$0.24
EPS Est.
-$0.22
EPS Surpr.
-5.7%
Revenue
$0.02B
Q2 FY2025
May 12, 2025Miss
EPS Actual
-$0.18
EPS Est.
-$0.15
EPS Surpr.
-18.1%
Revenue
$0.01B
Q1 FY2025
Mar 13, 2025Beat
EPS Actual
$0.06
EPS Est.
-$0.18
EPS Surpr.
+132.9%
Revenue
$0.01B
Q4 FY2024
Nov 4, 2024Beat
EPS Actual
-$0.23
EPS Est.
-$0.24
EPS Surpr.
+3.7%
Revenue
$0.02B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.15 | $-0.11 | $-0.04 | 1 |
| Q3 FY2027 | $-0.11 | $-0.08 | $-0.03 | 1 |
| Q2 FY2027 | $-0.59 | $-0.42 | $-0.15 | 1 |
| Q1 FY2027 | $-0.52 | $-0.37 | $-0.13 | 1 |
| Q4 FY2026 | $-0.33 | $-0.24 | $-0.08 | 1 |
| Q3 FY2026 | $-0.32 | $-0.23 | $-0.08 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.1B | $0.1B | $0.2B | 3 |
| Q3 FY2027 | $0.0B | $0.1B | $0.1B | 2 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 11, 2026 | +30.7% | $3.08 | $3.08 | +0.00% |
| ▼ Q1 FY2026 | Mar 19, 2026 | -26.6% | $4.40 | $4.40 | +0.00% |
| ▲ Q4 FY2025 | Nov 7, 2025 | +102.5% | $5.04 | $5.04 | +0.00% |
| ▼ Q3 FY2025 | Aug 4, 2025 | -5.7% | $3.12 | $3.12 | +0.00% |
| ▼ Q2 FY2025 | May 12, 2025 | -18.1% | $1.25 | $1.25 | +0.00% |
| ▲ Q1 FY2025 | Mar 13, 2025 | +132.9% | $1.25 | $1.25 | +0.00% |
| ▲ Q4 FY2024 | Nov 4, 2024 | +3.7% | $2.54 | $2.54 | +0.00% |
| ▲ Q3 FY2024 | Aug 6, 2024 | -0.8% | $2.54 | $2.54 | +0.00% |
Q2 FY2026+0.00%
Report Date
May 11, 2026
EPS Beat/Miss
+30.7%
Price Before
$3.08
Price After
$3.08
Q1 FY2026+0.00%
Report Date
Mar 19, 2026
EPS Beat/Miss
-26.6%
Price Before
$4.40
Price After
$4.40
Q4 FY2025+0.00%
Report Date
Nov 7, 2025
EPS Beat/Miss
+102.5%
Price Before
$5.04
Price After
$5.04
Q3 FY2025+0.00%
Report Date
Aug 4, 2025
EPS Beat/Miss
-5.7%
Price Before
$3.12
Price After
$3.12
Q2 FY2025+0.00%
Report Date
May 12, 2025
EPS Beat/Miss
-18.1%
Price Before
$1.25
Price After
$1.25
Q1 FY2025+0.00%
Report Date
Mar 13, 2025
EPS Beat/Miss
+132.9%
Price Before
$1.25
Price After
$1.25
Q4 FY2024+0.00%
Report Date
Nov 4, 2024
EPS Beat/Miss
+3.7%
Price Before
$2.54
Price After
$2.54
Q3 FY2024+0.00%
Report Date
Aug 6, 2024
EPS Beat/Miss
-0.8%
Price Before
$2.54
Price After
$2.54
Avg Beat Reaction+0.00%
Avg Miss Reaction+0.00%
Beat Rate5 / 8 quarters
Largest Move+0.00% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CMVLF ends December
Cellectis S.A. (CMVLF) most recently reported earnings on May 11, 2026 for Q2 FY2026, posting EPS of $-0.18 — beating the analyst consensus of $-0.26 by +30.7%. The next CMVLF earnings date is expected around September 1, 2026.
Each quarter, investors track CMVLF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CMVLF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CMVLF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CMVLF earnings · 5 questionsCellectis S.A.'s next earnings report is expected around September 1, 2026. CMVLF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CMVLF historically reports after market close (AMC).
CMVLF earnings datewhen is CMVLF earningsCMVLF next earnings datewhen does CMVLF report earningsCMVLF earnings calendar
▸ Source: FMP · Cellectis S.A. SEC filings · US GAAP · Cellectis S.A. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026